Navigation Links
VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment

BOSTON October 25, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced the results of a study which demonstrated that adults with Attention Deficit Hyperactivity Disorder (ADHD) experienced significant improvements in ADHD symptom control within one week of treatment with once-daily VYVANSE (lisdexamfetamine dimesylate), the first prodrug stimulant. Findings from this phase III pivotal trial were presented today at a national psychiatric meeting in Boston, Mass.

Adults with ADHD may experience significant impairments in their ability to focus, and organize and complete tasks, which could affect their work, family life and personal relationships, said Lenard A. Adler, M.D., lead researcher in this study and director of the Adult ADHD Program at New York University School of Medicine and author of Scattered Minds: Help and Hope for Adults with ADHD. The results of this study demonstrated that VYVANSE significantly improved the core symptoms of ADHD in adult study patients.

Results of Phase III Pivotal Trial

In this double-blind, placebo-controlled, four-week study with dose escalations in 414 adults aged 18 to 55 years, treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) was significantly more effective than placebo and improvements were observed in the first week of the study.

All doses of VYVANSE showed significant improvements in the average change in ADHD Rating Scale (ADHD-RS-IV) scores, as measured from the studys start to end, the primary endpoint of this study. ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD and for assessing their response to treatment. The scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, a publication of the American Psychiatric Association.

VYVANSE provided a significant reduction in ADHD-RS-IV scores starting at week one that were observed throughout the full treatment period. At endpoint, VYVANSE provided a significant reduction in ADHD-RS-IV scores ranging from 16.2 to 18.6 points.

Investigators also measured the efficacy of VYVANSE with the Clinical Global Impressions-Improvement (CGI-I) scale, a standard assessment used to rate the severity of a patients illness and improvement over time. The study found that the percentage of subjects taking VYVANSE rated improved on the CGI-I scale ranged from 57 to 61 percent across all doses and was significantly greater than placebo.

The study showed there were no statistically significant differences among the groups for total score of Pittsburgh Sleep Quality Index (PSQI) at endpoint with all groups showing a slight decrease in the PSQI total score at endpoint. The PSQI is a self-rated questionnaire that assesses sleep quality and disturbances over a one-month time interval.

Adverse events reported in this study were generally mild to moderate and included dry mouth (26 percent), decreased appetite (27 percent) and insomnia (19 percent).

VYVANSE is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The pharmacokinetic profile of VYVANSE is inherent to its chemical prodrug nature and alterations in gastric pH and gastrointestinal motility do not affect its absorption.

A supplemental New Drug Application (sNDA) for VYVANSE for the treatment of ADHD in adults is currently under review by the U.S. Food and Drug Administration (FDA). VYVANSE is currently approved in the United States for the treatment of ADHD in children aged 6 to 12 years.


Contact: Jacelyn Seng
Porter Novelli

Related medicine news :

1. VYVANSE(TM) Drug for the Treatment of ADHD in Adults
2. Man against HIV – new vaccine ready for human trials
3. FDA approves Phase 0 trial which tests experimental drugs on humans
4. Male contraceptive in trial
5. How do patients benefit of clinical trials
6. Glenmark’s new molecule to go through trial
7. Clinical trials need to be more frank
8. First head-to-head trials of once weekly Fosamax and Actonel therapies
9. Hormone Replacement Therapy increases the risk of endometrial cancer
10. Atrial fibrillation predicts for acute ischaemic stroke
11. Spray on contraceptive clears Phase I trial
Post Your Comments:
(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
Breaking Medicine Technology: